Abstract: An embolization device for occluding a body cavity includes one or more elongated, expansible, hydrophilic embolizing elements non-releasably carried along the length of an elongated filamentous carrier that is preferably made of a very thin, highly flexible filament or microcoil of nickel/titanium alloy. At least one expansile embolizing element is non-releasably attached to the carrier. A first embodiment includes a plurality of embolizing elements fixed to the carrier at spaced-apart intervals along its length. In second, third and fourth embodiments, an elongate, continuous, coaxial embolizing element is non-releasably fixed to the exterior surface of the carrier, extending along a substantial portion of the length of the carrier proximally from a distal tip, and optionally includes a lumenal reservoir for delivery of therapeutic agents. Exemplary methods for making these devices include skewering and molding the embolizing elements.

Abstract: Embodiments of the invention accelerate at least one special purpose processor, such as a GPU, or a driver managing a special purpose processor, by using at least one co-processor. Advantageously, embodiments of the invention are fault-tolerant in that the at least one GPU or other special purpose processor is able to execute all computations, although perhaps at a lower level of performance, if the at least one co-processor is rendered inoperable. The co-processor may also be used selectively, based on performance considerations.

Abstract: A shipping container for integrated circuit wafers has a lower section and an upper section releasably connected to the lower section, and a seal is received on a shoulder of the lower section. The seal is in contact with a lower edge portion of the upper section and extends in a flat reference plane when the sections are assembled together in order to help protect the wafers from moisture, airborne particulates and/or other contaminates. The shipping container also preferably includes at least one info pad plug that comprises a body and an adhesive for connecting the body to the lower section of the container.

Abstract: A method for calculating a parameter from an image sequence includes selecting a first frame and a second frame in an image sequence. The image sequence has a frame speed. The image sequence or another image sequence is enhanced using a calculation that considers the frame speed and selected frames. The enhancement may be with text, graphics or both such as those that may present statistics corresponding to an event in the image sequence.

Abstract: The present invention provides for implant device delivery apparatuses and related methods of use. An apparatus of the present invention may include a pusher member selectively engaged to an implant device. The implant device may be, e.g., a coil. A coupling section of the apparatus allows the implant device to be secured to the pusher member via an application of energy. When it is desired to disengage the implant device, such as after locating the implant device at a target cavity site, the application of energy is ceased and the implant device may be disengaged from the pusher member.

Abstract: The present invention provides a technique for securely implementing port-based authentication on a shared media port in an intermediate node, such as a router. To that end, the invention provides enhanced port-based network access control that includes client-based control at the shared media port. Unlike previous implementations, the port does not permit multiple client nodes to access a trusted subnetwork as soon as a user at any one of those nodes is authenticated by the subnetwork. Instead, port-based authentication is performed for every client node that attempts to access the trusted subnetwork through the shared media port. As such, access to the trusted subnetwork is not compromised by unauthenticated client nodes that “piggy-back” over the shared media port after a user at another client node has been authenticated by the trusted subnetwork.

Abstract: The present application discloses an apparatus for treating vascular aneurysms and includes an occlusive support device comprised of one or more support members. The occlusive device has a first end portion and a second end portion, an end cap member at the first end portion of the occlusive support device, and an anchoring member at the second end portion. The end cap member is comprised of at least one of one or more of the support members. The end cap member has openings and the end cap member comprises a reactive material that is configured to hydrate upon delivery of the device and to reduce the size of said openings. The end cap member has an end cap diameter and the end cap is generally perpendicular to the longitudinal axis of the support device. The end cap has an extension along the longitudinal axis of said device that is less than two times the end cap diameter.

Abstract: A real-time system and method for inserting perspective correct content into an image sequence are presented. The invention inserts the content with the location, size, orientation, shape and occlusion properties that are appropriate for the camera view represented by the image sequence. Both static and dynamic content insert positions are supported. The location, size, orientation and shape of the inserted content are determined independently of the image sequence content. Furthermore, no knowledge of three dimensional real world space locations or real world measurements, as related to the content of the image sequence, is used during the content insert process.

Abstract: Methods and apparatus for treating or preventing endoleaks after an endovascular graft (e.g., a stent, tubular graft, stent-graft, coated stent, covered stent, intravascular flow modifier or other endovascular implant that affects, limits or prevents blood flow into a vascular defect such as an aneurysm, arterio-venous fistula, arterio-venous malformation, vessel wall perforation, etc.) has been implanted in the vasculature of a human or veterinary patient. An expansile polymeric material, such as a swellable polymer (e.g., a hydrogel), a flexible or elastomeric polymer foam (e.g. silicone, polyurethane, etc.) or a carrier member (e.g, a coil, filament, wire, etc) that carries a quantity of such expansile polymer is delivered into a perigraft space (i.e., space between the endovascular graft and the surrounding blood vessel wall) such that the polymeric material expands in situ to substantially fill the perigraft space or a portion thereof.

Abstract: Medical devices for insertion into the body of human or veterinary patients, wherein the device comprises a) a working element (e.g. a wire, a guidewire, a tube, a catheter, a cannula, a scope (e.g., rigid or flexible endoscope, laparoscope, sigmoidoscope, cystoscope, etc.) a probe, an apparatus for collecting information from a location within the body (e.g., an electrode, sensor, camera, scope, sample withdrawal apparatus, biopsy or tissue sampling device, etc.) which has an outer surface and b) a continuous or non-continuous coating on the outer surface of the working element. The outer surface of the working element is prepared to create a surface topography which promotes mechanical or frictional engagement of the coating to the working element. In some embodiments the coating is a lubricious coating, such as a fluorocarbon coating or a hydrogel that becomes lubricious when contacted by a liquid. In some embodiments, the coating may expand as swell.

Abstract: A mechanism for the deployment of a filamentous endovascular device includes a flexible deployment tube having an open proximal end, and a coupling element attached to the proximal end of the endovascular device. The deployment tube includes a distal section terminating in an open distal end, with a lumen defined between the proximal and distal ends. A retention sleeve is fixed around the distal section and includes a distal extension extending a short distance past the distal end of the deployment tube. The endovascular device is attached to the distal end of the deployment tube by fixing the retention sleeve around the coupling element, so that the coupling element is releasably held within the distal extension of the deployment tube. In use, the deployment tube, with the implant attached to its distal end, is passed intravascularly through a microcatheter to a target vascular site until the endovascular device is located within the site.

Abstract: There are provided according to the invention, novel compounds of formula (I) wherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory disease.

Abstract: A loudspeaker system designed for ceiling installation. The system includes a woofer, a midrange speaker and a tweeter commonly supported on a rotatable support member which in turn is supported on and is rotatable with respect to an annular rim that is designed to be fixed about an opening in the ceiling. The woofer is aligned at one acute angle and the midrange speaker and tweeter at another acute angle to the annular rim. The mid range speaker and tweeter are partially segregated from the woofer by a baffle.

Abstract: A compound of formula (I): or a salt, solvate or physiologically functional derivative thereof for use as a IK and/or SK channel opener. Methods of screening SK ion channels, particularly SK1 and medicaments for the treatment of a urinogenital, respiratory, cardiovascular, neuronal disorder, of sleeping disorders, sickle cell anemia, pain, inflammation and bowel disease (IBD) are also disclosed.

Abstract: There are disclosed according to the invention, compounds of formula (I) wherein R1, R2 and R3 are defined in the specification. Additionally, processes of preparing the compounds of formula (I), formulations containing same, and the administration of said compounds or formulations thereof in the treatment of inflammatory diseases are also disclosed.

Abstract: Compounds of formula (I) where R1 is phenyl substituted by one or more halogen atoms, naphthyl and naphthyl substituted by one or more halogen atoms; R2 is —NH2 and —NHC(═O)Ra; R3 is —NRbRc, —NHC(═O)Ra or hydrogen; R4 is hydrogen, —C1-4 alkyl, —CN, —CH2OH, —CH2ORd, —CH2S(O)xRd and —C1-4 alkyl substituted by one or more halogen atoms in which Ra represents C1-4 alkyl or C3-7cycloalkyl, and Rb and Rc, which may be the same or different, are hydrogen or C1-4 alkyl, or together with the nitrogen atom to which they are attached, form a 6-membered nitrogen containing heterocycle, which heterocycle can be further substituted with one or more C1-4 alkyl; Rd is C1-4 alkyl or C1-4 alkyl substituted by one or more halogen atoms; x is an integer zero, one or two; and salts, solvates and prodrugs thereof, provided that R1 does not represent: when R2 is —NH2, and both R3 and R4 are hydrogen.

Abstract: A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.

Abstract: There are provided according to the invention novel compounds of formula I wherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

Abstract: A compound of formula (I) wherein R1 is phenyl substituted by one or more halogen atoms; R2 is —NH2; R3 is —NH2 or hydrogen; R4 is —CXNRaRb, —CXNH—(CH2)y—NRaRb; wherein X is ═O or ═S; y is an integer zero, 1 or 2; Ra and Rb, which may be the same or different, are selected from hydrogen and C1-4 alkyl or together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocycle containing one or two nitrogen heteroatoms, which heterocycle can be further substituted with one or more C1-4 alkyl groups; and pharmaceutically acceptable derivatives thereof.

Abstract: A compound of formula (I) wherein R1 is phenyl substituted by one or more halogen atoms; R2 is —NH2; R3 is —NH2 or hydrogen; R4 is —CXNRaRb, —CXNH—(CH2)y—NRaRb; wherein X is ═O or +S; y is an integer zero, 1 or 2; Ra and Rb, which may be the same or different, are selected from hydrogen and C1-4 alkyl or together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocycle containing one or two nitrogen heteroatoms, which heterocycle can be further substituted with one or more C1-4 alkyl groups; and pharmaceutically acceptable derivatives thereof.